Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784028 | 0.84 | SLC6A4 (0.38) | HTTDPP4DPP8DPP9DPP7 | |
| SCHEMBL17784080 | 0.84 | KDM4E (0.36) | LMNARAB9A | |
| SCHEMBL17784103 | 0.81 | NPC1 (0.47) | HTTRAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17784040 | 0.78 | LMNA (0.38) | LMNAMAPK1HTTRAB9AHPGD | |
| SCHEMBL17784109 | 0.75 | LMNA (0.38) | LMNAMAPK1HTTRAB9AHPGD | |
| SCHEMBL17784107 | 0.75 | SLC6A4 (0.38) | HTTDPP4DPP8DPP9DPP7 | |
| SCHEMBL17784052 | 0.74 | NPC1 (0.48) | HTTRAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1139419 | 0.73 | ALDH1A1 (0.39) | RAB9AHPGDGRIK1GRIA2ALDH1A1 | |
| SCHEMBL17784021 | 0.73 | MEN1 (0.39) | LMNAMAPK1HTTRAB9ATSHR | |
| SCHEMBL17784050 | 0.73 | RARA (0.37) | LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| EP-3227262-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | Novira Therapeutics Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | LMNA 4148/4885MAPK1 3024/4885HTT 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.